FI3814348T3 - Substituoituja naftyridinoniyhdisteitä, jotka ovat käyttökelpoisia t-solun aktivoijina - Google Patents
Substituoituja naftyridinoniyhdisteitä, jotka ovat käyttökelpoisia t-solun aktivoijina Download PDFInfo
- Publication number
- FI3814348T3 FI3814348T3 FIEP19744923.4T FI19744923T FI3814348T3 FI 3814348 T3 FI3814348 T3 FI 3814348T3 FI 19744923 T FI19744923 T FI 19744923T FI 3814348 T3 FI3814348 T3 FI 3814348T3
- Authority
- FI
- Finland
- Prior art keywords
- alkyl
- substituted
- och
- methyl
- cyclopropyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690439P | 2018-06-27 | 2018-06-27 | |
| US201962840459P | 2019-04-30 | 2019-04-30 | |
| PCT/US2019/039135 WO2020006018A1 (en) | 2018-06-27 | 2019-06-26 | Substituted naphthyridinone compounds useful as t cell activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3814348T3 true FI3814348T3 (fi) | 2023-09-22 |
Family
ID=67439335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19744923.4T FI3814348T3 (fi) | 2018-06-27 | 2019-06-26 | Substituoituja naftyridinoniyhdisteitä, jotka ovat käyttökelpoisia t-solun aktivoijina |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10669272B2 (https=) |
| EP (1) | EP3814348B9 (https=) |
| JP (1) | JP7432532B2 (https=) |
| KR (1) | KR102767739B1 (https=) |
| CN (1) | CN112654621B (https=) |
| AU (1) | AU2019291794B2 (https=) |
| BR (1) | BR112020026681A2 (https=) |
| CA (1) | CA3104654A1 (https=) |
| CL (1) | CL2020003260A1 (https=) |
| CY (1) | CY1126280T1 (https=) |
| DK (1) | DK3814348T3 (https=) |
| ES (1) | ES2960754T3 (https=) |
| FI (1) | FI3814348T3 (https=) |
| HR (1) | HRP20231253T1 (https=) |
| HU (1) | HUE064531T2 (https=) |
| IL (1) | IL279728B2 (https=) |
| LT (1) | LT3814348T (https=) |
| MX (1) | MX2020013817A (https=) |
| PE (1) | PE20210469A1 (https=) |
| PL (1) | PL3814348T3 (https=) |
| PT (1) | PT3814348T (https=) |
| RS (1) | RS64641B1 (https=) |
| SG (1) | SG11202012972YA (https=) |
| SI (1) | SI3814348T1 (https=) |
| SM (1) | SMT202300466T1 (https=) |
| TW (1) | TW202019924A (https=) |
| WO (1) | WO2020006018A1 (https=) |
| ZA (1) | ZA202100555B (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111471059B (zh) * | 2019-01-23 | 2022-12-02 | 药捷安康(南京)科技股份有限公司 | Pde9抑制剂及其用途 |
| AU2020266529B2 (en) | 2019-04-29 | 2026-01-29 | Solent Therapeutics, Llc | 3-amino-4H-benzo[E][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2 |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| CN115210225A (zh) | 2019-11-28 | 2022-10-18 | 拜耳公司 | 取代的氨基喹诺酮类作为免疫激活的dgkalpha抑制剂 |
| US20230064809A1 (en) | 2019-11-28 | 2023-03-02 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| KR20220122637A (ko) | 2019-11-28 | 2022-09-02 | 바이엘 악티엔게젤샤프트 | 면역 활성화를 위한 dgk알파 억제제로서의 치환된 아미노퀴놀론 |
| BR112022009631A2 (pt) * | 2019-12-19 | 2022-08-09 | Bristol Myers Squibb Co | Combinações de inibidores de dgk e antagonistas do ponto de checagem |
| KR20220119456A (ko) * | 2019-12-23 | 2022-08-29 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 퀴놀리노닐 피페라진 화합물 |
| AR120823A1 (es) * | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| IL294273A (en) * | 2019-12-23 | 2022-08-01 | Bristol Myers Squibb Co | Substituted heteroaryl compounds are useful as t-cell activators |
| EP4081522A1 (en) * | 2019-12-23 | 2022-11-02 | Bristol-Myers Squibb Company | Substituted piperazine derivatives useful as t cell activators |
| CN114846007B (zh) | 2019-12-23 | 2024-11-22 | 百时美施贵宝公司 | 可用作t细胞激活剂的经取代的喹唑啉基化合物 |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| AR120896A1 (es) * | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz |
| PL4139286T3 (pl) | 2020-04-24 | 2025-08-11 | Bayer Aktiengesellschaft | Podstawione aminotiazole jako inhibitory dgkzeta do aktywacji immunologicznej |
| WO2021258010A1 (en) * | 2020-06-19 | 2021-12-23 | Gossamer Bio Services, Inc. | Oxime compounds useful as t cell activators |
| CN116615199A (zh) * | 2020-11-26 | 2023-08-18 | 株式会社Lg化学 | 作为二酰基甘油激酶抑制剂的杂环化合物及其用途 |
| AR124172A1 (es) * | 2020-11-30 | 2023-02-22 | Astellas Pharma Inc | Compuesto de heteroarilcarboxamida |
| EP4262986A1 (en) | 2020-12-16 | 2023-10-25 | Gossamer Bio Services, Inc. | Compounds useful as t cell activators |
| JP2024509853A (ja) | 2021-03-03 | 2024-03-05 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法およびｄｇｋ阻害剤の組合せ |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2023122777A1 (en) * | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| EP4472963A1 (en) * | 2022-02-01 | 2024-12-11 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| WO2023165525A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| KR20240156394A (ko) | 2022-03-01 | 2024-10-29 | 인실리코 메디신 아이피 리미티드 | 디아실글리세롤 키나아제 (dgk) 알파 억제제 및 이의 용도 |
| CN118829642A (zh) * | 2022-03-01 | 2024-10-22 | 英矽智能科技知识产权有限公司 | 二酰基甘油激酶(DGK)α抑制剂及其用途 |
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
| WO2023184327A1 (en) * | 2022-03-31 | 2023-10-05 | InventisBio Co., Ltd. | Kinase inhibitors, preparation methods and uses thereof |
| US12600723B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US12600722B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US20240083898A1 (en) * | 2022-08-15 | 2024-03-14 | Incyte Corporation | Tricyclic triazolo compounds as dgk inhibitors |
| CN120152717A (zh) | 2022-09-08 | 2025-06-13 | 朱诺治疗学股份有限公司 | T细胞疗法和连续或间歇dgk抑制剂给药的组合 |
| AR131786A1 (es) | 2023-02-06 | 2025-04-30 | Bayer Ag | Combinación de anticuerpos ccr8 con inhibidores de dgk |
| CN116375654B (zh) * | 2023-03-22 | 2024-12-31 | 湖北三峡实验室 | 一种由双甘肽制备2,5-二酮哌嗪的方法 |
| CN119143715B (zh) * | 2024-11-12 | 2025-03-14 | 天津匠新致成科技有限公司 | 二芳基团甲基哌嗪类化合物及其制备方法、药物组合物和应用 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4324893A (en) | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| MY140679A (en) | 2001-05-24 | 2010-01-15 | Avanir Pharmaceuticals | Inhibitors of macrohage migration inhibitory factor and methods for identifying the same |
| WO2004002960A1 (en) | 2002-06-27 | 2004-01-08 | Schering Aktiengesellschaft | Substituted quinoline ccr5 receptor antagonists |
| GB0230018D0 (en) | 2002-12-23 | 2003-01-29 | Syngenta Ltd | Fungicides |
| TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| JP2006521400A (ja) | 2003-03-26 | 2006-09-21 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 糖尿病及び関連障害の処置のための化合物及びそれらの使用 |
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| AU2004259755A1 (en) | 2003-07-22 | 2005-02-03 | Janssen Pharmaceutica, N.V. | Quinolinone derivatives as inhibitors of c-fms kinase |
| EP1656376A1 (en) * | 2003-08-22 | 2006-05-17 | Avanir Pharmaceuticals | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases |
| US7381401B2 (en) * | 2004-01-08 | 2008-06-03 | The University Of Chicago | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2634198C (en) | 2005-12-20 | 2014-06-03 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| GB0605689D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| JP2007308402A (ja) | 2006-05-17 | 2007-11-29 | Sumitomo Chemical Co Ltd | シンナモイル化合物及びその用途 |
| JP2007308441A (ja) | 2006-05-22 | 2007-11-29 | Sumitomo Chemical Co Ltd | 含複素環化合物及びその用途 |
| ES2444574T3 (es) | 2006-09-19 | 2014-02-25 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ｉｄｏ阻害剤 |
| US20110176972A1 (en) | 2008-05-29 | 2011-07-21 | Saint-Gobain Centre De Recherches et D'Etudes Eur | Cellular structure containing aluminium titanate |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US20110281908A1 (en) | 2008-10-06 | 2011-11-17 | Emory University | Aminoquinoline Derived Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| US20110319416A1 (en) | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | Anti-gitr antibodies |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| PH12012500881A1 (en) | 2009-12-10 | 2017-07-26 | Hoffmann La Roche | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| CA2789076C (en) | 2010-03-05 | 2017-11-21 | F. Hoffmann-La Roche Ag | Antibodies against human colony stimulating factor-1 receptor and uses thereof |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| MX378336B (es) | 2010-05-04 | 2025-03-10 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| EP2592933B1 (en) | 2010-07-16 | 2017-04-05 | Anderson Gaweco | Mif inhibitors and their uses |
| PT2614082T (pt) | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| US9133164B2 (en) | 2011-04-13 | 2015-09-15 | Innov88 Llc | MIF inhibitors and their uses |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
| RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
| WO2013118071A1 (en) | 2012-02-09 | 2013-08-15 | Glenmark Pharmaceuticals S.A. | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| EP2847220A1 (en) | 2012-05-11 | 2015-03-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2014039513A2 (en) | 2012-09-04 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive t cell transfer |
| JP2018513853A (ja) | 2015-04-10 | 2018-05-31 | アラクセス ファーマ エルエルシー | 置換キナゾリン化合物およびその使用方法 |
| CA3005766A1 (en) | 2015-12-17 | 2017-06-22 | Merck Patent Gmbh | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
| CN107216325B (zh) | 2016-03-22 | 2019-06-25 | 上海医药工业研究院 | 萘啶酮类化合物、及其制备方法和应用 |
| US10946020B2 (en) | 2016-04-06 | 2021-03-16 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
| WO2018119183A2 (en) | 2016-12-22 | 2018-06-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| WO2018134885A1 (ja) | 2017-01-17 | 2018-07-26 | 初実 田中 | 支援奨励システムおよび支援奨励方法 |
| GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| EA201992781A1 (ru) | 2017-05-22 | 2020-04-01 | Эмджен Инк. | Ингибиторы g12c kras и способы их применения |
| US12187687B2 (en) | 2017-06-26 | 2025-01-07 | University Of Virginia Patent Foundation | Compositions and uses thereof |
| PL3761980T3 (pl) | 2018-03-07 | 2024-06-10 | Pliant Therapeutics, Inc. | Związki aminokwasowe i sposoby zastosowania |
| US20210238136A1 (en) | 2018-06-07 | 2021-08-05 | Daiichi Sankyo Company, Limited | Azetidine derivative, and prodrug thereof |
| CN112469707B (zh) | 2018-06-27 | 2024-06-21 | 利伯纳生物科学株式会社 | 脊髓性肌萎缩症的预防剂或治疗剂 |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| BR112020026580A2 (pt) | 2018-06-27 | 2021-03-23 | Proteostasis Therapeutics, Inc. (Fem) | Compostos, composição farmacêutica e métodos para tratar um paciente |
| MX2020013895A (es) | 2018-06-27 | 2021-07-21 | Biogen Ma Inc | Agentes inhibidores de ask1. |
| MY204443A (en) | 2018-06-27 | 2024-08-28 | Oscotec Inc | Pyridopyrimidinone derivatives for use as axl inhibitors |
| TWI833770B (zh) | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | 用於減少 lrrk2 表現之化合物及方法 |
-
2019
- 2019-06-26 CN CN201980055715.8A patent/CN112654621B/zh active Active
- 2019-06-26 HU HUE19744923A patent/HUE064531T2/hu unknown
- 2019-06-26 PE PE2020002111A patent/PE20210469A1/es unknown
- 2019-06-26 AU AU2019291794A patent/AU2019291794B2/en not_active Ceased
- 2019-06-26 CA CA3104654A patent/CA3104654A1/en active Pending
- 2019-06-26 FI FIEP19744923.4T patent/FI3814348T3/fi active
- 2019-06-26 US US16/452,679 patent/US10669272B2/en active Active
- 2019-06-26 PL PL19744923.4T patent/PL3814348T3/pl unknown
- 2019-06-26 HR HRP20231253TT patent/HRP20231253T1/hr unknown
- 2019-06-26 WO PCT/US2019/039135 patent/WO2020006018A1/en not_active Ceased
- 2019-06-26 LT LTEPPCT/US2019/039135T patent/LT3814348T/lt unknown
- 2019-06-26 SM SM20230466T patent/SMT202300466T1/it unknown
- 2019-06-26 DK DK19744923.4T patent/DK3814348T3/da active
- 2019-06-26 MX MX2020013817A patent/MX2020013817A/es unknown
- 2019-06-26 RS RS20230895A patent/RS64641B1/sr unknown
- 2019-06-26 ES ES19744923T patent/ES2960754T3/es active Active
- 2019-06-26 EP EP19744923.4A patent/EP3814348B9/en active Active
- 2019-06-26 BR BR112020026681-7A patent/BR112020026681A2/pt unknown
- 2019-06-26 PT PT197449234T patent/PT3814348T/pt unknown
- 2019-06-26 JP JP2020572691A patent/JP7432532B2/ja active Active
- 2019-06-26 KR KR1020217002231A patent/KR102767739B1/ko active Active
- 2019-06-26 SG SG11202012972YA patent/SG11202012972YA/en unknown
- 2019-06-26 SI SI201930609T patent/SI3814348T1/sl unknown
- 2019-06-27 TW TW108122537A patent/TW202019924A/zh unknown
-
2020
- 2020-04-08 US US16/843,024 patent/US10954238B1/en active Active
- 2020-12-16 CL CL2020003260A patent/CL2020003260A1/es unknown
- 2020-12-23 IL IL279728A patent/IL279728B2/en unknown
-
2021
- 2021-01-26 ZA ZA2021/00555A patent/ZA202100555B/en unknown
- 2021-02-01 US US17/164,009 patent/US11713316B2/en active Active
-
2023
- 2023-10-31 CY CY20231100606T patent/CY1126280T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3814348T3 (fi) | Substituoituja naftyridinoniyhdisteitä, jotka ovat käyttökelpoisia t-solun aktivoijina | |
| CN106220581A (zh) | 含氟杂环化合物及其制备方法 | |
| Maes et al. | Suzuki reactions on chloropyridazinones: an easy approach towards arylated 3 (2H)-pyridazinones | |
| AR091516A1 (es) | Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida | |
| CN109415319A (zh) | 通过直接苏楚基偶联合成芳基羧酸酯 | |
| Liu et al. | A General, Effcient and Green Procedure for Synthesis of Dihydropyrimidine‐5‐carboxamides in Low Melting Betaine Hydrochloride/Urea Mixture | |
| CN104030989A (zh) | 一种瑞舒伐他汀钙的制备方法 | |
| CN107501326A (zh) | 一种化合物及其制备方法、用途和阻燃材料 | |
| CN104692985B (zh) | 钯催化合成α-芳基、杂芳基或烯基-α,α-二氟烯丙基结构的方法 | |
| Nobre et al. | Elemental chalcogen (Se, S) in PEG-400 to the synthesis of seleno-and thioflavones from 2-chlorophenyl ethynyl ketone and nucleophilic species of chalcogen | |
| CN106565704B (zh) | 一种咪唑并[1,2-a]吡啶的芳基化方法 | |
| CN104829581A (zh) | 一种6-溴吡喃衍生物的制备方法 | |
| CN104447764A (zh) | 吡咯并吡咯二酮衍生物及其合成方法 | |
| AU6543600A (en) | Process for the preparation of pyrazolo(4,3-d)pyrimidin-7- ones-3-pyridylsulphonyl compounds and intermediates thereof | |
| CN104844549A (zh) | 一种7-溴吡喃衍生物的制备方法 | |
| CN104829575A (zh) | 一种6-氟吡喃衍生物的制备方法 | |
| JP6240346B2 (ja) | ロスバスタチンカルシウムを製造するための中間体化合物、及びそれを用いてロスバスタチンカルシウムを製造する方法 | |
| WO2025219579A1 (en) | Klhdc2 (kelch domain-containing protein 2) ligase ligands | |
| CN104829600B (zh) | 一种合成瑞舒伐他汀的中间体的合成工艺 | |
| WO2016004899A1 (en) | Process for making tetracyclic heterocycle compounds | |
| CN103242378B (zh) | 二茂铁基嘧啶钳形配体及其制备方法 | |
| CN109336922A (zh) | 一种应用witting反应制备含膦α-酮酸酯的方法 | |
| KR101344076B1 (ko) | 마이크로웨이브 에너지를 이용한 테트라하이드로퀴놀린 화합물의 제조방법 | |
| CN109485605B (zh) | 一种10h-螺[吖啶-9,9`-芴]及其衍生物的制备方法 | |
| CN102690267A (zh) | 一种制备厄他培南中间体的方法 |